22.24
+1.28%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fortrea Holdings
From its filings with the US Securities and Exchange Commission
Fortrea Holdings is based in Durham, North Carolina. Its shares trade on Nasdaq under the ticker FTRE. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $2.72bn and a net loss of $986.2m. At that date it held total assets of $2.72bn and shareholders' equity of $563.5m.
Fortrea Holdings Inc. is a leading global contract research organization (“CRO”), providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology and medical device customers. We provide phase I through IV clinical trial management, clinical pharmacology, and consulting services for our customers. For more than 30 years, we have supported our global pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas, providing agile delivery models that include Full Service, Functional Service Provider (“FSP”), and Hybrid structures. We believe we are well positioned to leverage our global scale, scientific and therapeutic expertise, access to clinical data-driven insights, industry network, and decades of experience to bring customers distinctive, expert solutions.
Our team of approximately 14,300 employees is able to conduct operations in approximately 100 countries. Our solutions streamline the biopharmaceutical product and medical device development process.
Fortrea combines decades of domain expertise with the nimbleness required to meet market demand for flexible engagements with large and small customers, delivering solutions that bring life-changing treatments to patients faster and creating value for all stakeholders. Our expertise in the biopharmaceutical product and medical device development process has enabled us to design service offerings to better meet the needs of customers. We manage our business in one reporting segment — Clinical Services.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 16 Jun 2023
- Employees
- 14,300
- Head office
- 8 MOORE DRIVE, DURHAM, NC, 27709
- Classification
- Services-Medical Laboratories
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Peter NeupertChairman of the Board, since 2023$320,000
- Mr. Anshul ThakralaPresident, Chief Executive Officer, Director, since 2025
- Ms. Jill McconnellChief Financial Officer$1.3m
- Mr. Mark MoraisChief Operating Officer and President - Clinical Services$1.3m
- Dr. Amrit RayLead Independent Director$300,000
- Mr. William SharbaughDirector
- Mr. Edward PesickaIndependent Director$300,000
- Ms. Erin RussellIndependent Director
- Ms. Machelle SandersIndependent Director$277,500
- Mr. David SmithIndependent Director$325,000
- Ms. Hima InguvaInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 54
- Social
- 60
- Governance
- 39
- Direct emissions (scope 1)
- 864 t
- Energy emissions (scope 2)
- 7,424 t
- Women in the workforce
- 30%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fortrea Holdings Inc employs 14300 employees in Durham, North Carolina.
- Fortrea provides comprehensive Phase I through IV clinical trial management services globally.
- Fortrea has scientific expertise in cardiovascular and cell and gene therapies segments.
Weaknesses
- Fortrea's IPO listing date was 16 June 2023, which is recent.
- Fortrea's headquarters city is Durham, North Carolina, a location with limited industry presence.
- Fortrea's employee count is 14300, which is lower than the industry average.
Opportunities
- Fortrea's global solutions include Clinical Development and Drug Development Consulting Services.
- Fortrea's therapeutic areas include cardiovascular and infectious disease segments.
- Fortrea's Enabling Services segment offers patient access solutions.
Threats
- Fortrea's Clinical Services segment faces competition from established players in the Life Sciences Tools & Services industry.
- Fortrea's Enabling Services segment must navigate regulatory changes in the Health Care sector.
- Fortrea's global presence requires managing geopolitical risks in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.